Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Abendstein Kjellmo

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Biomedicines|August 6, 2021
High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?Knut Tore Lappegård, Christian Abendstein Kjellmo, Anders Hovland
Diseases (Basel, Switzerland)|June 5, 2018
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?Christian Abendstein Kjellmo, Anders Hovland, Knut Tore Lappegård
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 6, 2018
Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot studyKnut Tore Lappegård, Christian Abendstein Kjellmo, Stefan Ljunggren, et al.
Journal of Clinical Lipidology|November 18, 2017
Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacityChristian Abendstein Kjellmo, Helen Karlsson, Torunn K Nestvold, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Biomedicines|August 6, 2021
High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?Knut Tore Lappegård, Christian Abendstein Kjellmo, Anders Hovland
Diseases (Basel, Switzerland)|June 5, 2018
CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?Christian Abendstein Kjellmo, Anders Hovland, Knut Tore Lappegård
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 6, 2018
Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot studyKnut Tore Lappegård, Christian Abendstein Kjellmo, Stefan Ljunggren, et al.
Journal of Clinical Lipidology|November 18, 2017
Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacityChristian Abendstein Kjellmo, Helen Karlsson, Torunn K Nestvold, et al.
Pageof 1